LIPTRUZET Drug Patent Profile

Which patents cover Liptruzet, and what generic alternatives are available?

Liptruzet is a drug marketed by Organon and is included in one NDA.

The generic ingredient in LIPTRUZET is atorvastatin calcium; ezetimibe. There are sixty-two drug master file entries for this compound. Additional details are available on the atorvastatin calcium; ezetimibe profile page.

Summary for LIPTRUZET

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	13
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LIPTRUZET
DailyMed Link:	LIPTRUZET at DailyMed

US Patents and Regulatory Information for LIPTRUZET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	LIPTRUZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	200153-001	May 3, 2013		DISCN	Yes	No
Organon	LIPTRUZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	200153-004	May 3, 2013		DISCN	Yes	No
Organon	LIPTRUZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	200153-002	May 3, 2013		DISCN	Yes	No
Organon	LIPTRUZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	200153-003	May 3, 2013		DISCN	Yes	No

International Patents for LIPTRUZET

See the table below for patents covering LIPTRUZET around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	T73852
Taiwan	486467
Poland	182617
Japan	3254219
Eurasian Patent Organization	000474	КРИСТАЛЛИЧЕСКАЯ КИСЛАЯ КАЛЬЦИЕВАЯ СОЛЬ [R-(R*, R*)]-2-(4-ФТОРФЕНИЛ)-БЕТА, ДЕЛЬТА-ДИГИДРОКСИ-5-(1-МЕТИЛЭТИЛ)-3-ФЕНИЛ-4-[(ФЕНИЛАМИНО)КАРБОНИЛ]-1Н-ПИРРОЛ-1-ГЕПТАНОВОЙ КИСЛОТЫ (АТОРВАСТАТИН) (CRYSTALLINE [R-(R*, R*)]-2-(4-FLUOROPHENYL)-BETA, DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID HEMI CALCIUM SALT (ATORVASTATIN))
Poland	324496
Canada	2172149	DERIVES DE SUBSTITUTION HYDROXYLES D'AZETIDINONE, UTILES COMME AGENTS HYPOCHOLESTEROLEMIQUES (HYDROXY-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS)

Supplementary Protection Certificates for LIPTRUZET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	SPC/GB03/023	United Kingdom		PRODUCT NAME: EZETIMIBE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: DE 54486.00.00 20021017; DE 54488.00.00 20021017; DE 54487.00.00 20021017; DE 54489.00.00 20021017; UK PL 19945/0001 20030404; UK PL 19945/0002 20030404
0720599	C300688	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NAT. REGISTRATION NO/DATE: RVG114002-004RVG 114008-010 2014110811; FIRST REGISTRATION: 13-9663 - 9665 20140724
0720599	C00720599/02	Switzerland		FORMER OWNER: SCHERING CORPORATION, US
0720599	C300132	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATL REGISTRATION: RVG 28626 20030418; FIRST REGISTRATION: DE 54486.00.00, 54487.00.00, 54488.00.00, 54489.00.00 20021017
0720599	26/2005	Austria		PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON KOMBINIERT MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 1-25673 - 1-25676 20041228; FIRST REGISTRATION: DE 58874.00.00 - 58874.03.00; 58878.00.00 - 20040402
0720599	91160	Luxembourg		91160, EXPIRES: 20190914
0720599	CA 2005 00003	Denmark

LIPTRUZET Market Analysis and Financial Projection

Last updated: April 25, 2026

Market dynamics and financial trajectory for LIPTRUZET (ezetimibe + atorvastatin)

What is LIPTRUZET and how does it fit the dyslipidemia market?

LIPTRUZET is the fixed-dose combination (FDC) of ezetimibe + atorvastatin for lipid-lowering in primary hyperlipidemia and mixed dyslipidemia, including patients who need both an HMG-CoA reductase inhibitor and intestinal cholesterol absorption inhibition. The product aligns with the standard of care in dyslipidemia management: statins remain the anchor, while ezetimibe is used to intensify LDL-C reduction when statin monotherapy is insufficient or when combination therapy improves achievement of guideline targets.

Commercial model in this segment

• Non-rare, chronic use with predictable dosing patterns (once-daily oral).
• Therapy intensity driven by LDL-C targets and guideline adherence.
• Generic erosion risk concentrated on statin and ezetimibe components as patents expire across molecules and geographies.
• Switching behavior shaped by payer formularies and step edits (statin first, then combination).

Key implication for market dynamics: LIPTRUZET competes less on clinical differentiation and more on formulary placement, rebate execution, and patient persistence, with cost pressure rising as component generics expand.

---

How is the competitive landscape likely structured against LIPTRUZET?

The competitive set for an ezetimibe plus atorvastatin FDC typically includes:

• Generic atorvastatin + generic ezetimibe (therapeutic equivalence without an FDC form factor).
• On-formulary statins plus ezetimibe add-ons using separate pills.
• Other statin ezetimibe fixed combinations where available in a given market (depends on country-level approvals).

Competitive dynamics by payer stance

• If payers encourage 2-pill therapy (generic statin + generic ezetimibe), the FDC faces pricing pressure unless it achieves:
  • formulary tier advantage,
  • adherence lift sufficient to justify a premium,
  • or rebate depth that closes the cost gap.
• If payers favor FDCs for adherence and simplification, LIPTRUZET can sustain a net price advantage over the loose combination, but that advantage can compress quickly when competing generics enter.

---

What drives demand and uptake for a statin-ezetimibe FDC?

Demand drivers are anchored in behavior and policy, not novelty:

1. LDL-C target achievement: clinicians intensify therapy when LDL-C goals are not met on statin alone.
2. Guideline adherence and risk stratification: patients with higher cardiovascular risk are more likely to receive combination therapy earlier.
3. Adherence and persistence: FDCs reduce pill burden versus separate components, which can improve persistence rates in real-world use.
4. Coverage and step edits: payer rules determine whether ezetimibe is accessible without prolonged statin titration periods.

Market microstructure

• Prescriber switching often occurs when a payer changes its formulary policy or when net pricing becomes favorable.
• Pharmacy channel converts quickly once an FDC is on formulary with acceptable copays and rebate terms.
• Switch-back risk rises when generics are cheaper and payers remove incentives for FDCs.

---

What is the pricing and margin pressure profile for LIPTRUZET?

A statin-ezetimibe FDC faces a predictable margin squeeze pattern:

• Upfront entry economics: initial launch pricing and contracting can be supported by brand-like positioning (if exclusivity exists).
• Component genericization: as atorvastatin and/or ezetimibe generics expand across geographies, gross-to-net declines.
• FDC substitution: when separate generics are materially cheaper, payers can steer utilization away from the FDC unless rebates preserve parity.

Net sales sensitivity

• LIPTRUZET revenue is likely most sensitive to:
  • formulary tier changes,
  • rebate intensity,
  • and competitive net pricing by generic manufacturers of atorvastatin and ezetimibe.

---

How does exclusivity and patent timing shape the financial trajectory?

For a mature lipid-lowering class, financial trajectory is dominated by patent life and exclusivity windows at the product and jurisdiction level, plus any regulatory exclusivity that can delay generic entry.

For LIPTRUZET specifically, a complete and accurate financial trajectory requires confirmed details on:

• approval and launch date(s) by market,
• patent filing and expiry dates (composition, formulation, and method),
• exclusivity (if any) tied to reference products,
• AND observed generic entry timelines.

Those particulars are not included in the provided material, so a precise sales curve (ramp, peak, erosion onset, and erosion rate) cannot be stated without risking incorrect business conclusions.

What can be stated as a market mechanism (without inventing dates):

• If LIPTRUZET enters with protected status in a market, its early years typically show a ramp driven by formulary adoption.
• Financial performance then trends toward a downward net price trajectory upon generic availability for the component drugs or competing combinations.
• Later-stage declines are typically driven by payer switching to separate generics.

---

Where does LIPTRUZET sit in payer and channel decision-making?

In practice, FDC lipids often win or lose based on payer mechanics:

• Formulary access: preferred tier placement vs non-preferred status.
• Prior authorization (PA): requirements to document uncontrolled LDL-C on statin alone.
• Quantity limits: less common for chronic therapy but used in some systems during contracting.
• Copay structure: impacts adherence and refill persistence.
• Rebate execution: determines whether the FDC retains a net cost advantage after manufacturer rebates and payer contracting.

Financial relevance

• Gross margins for FDC brands can be pressured even when gross list price is stable, because net price falls with higher rebates during competitive bidding cycles.
• Real-world persistence can moderate volume erosion, but only if copays and coverage remain stable.

---

Financial trajectory: what patterns should investors expect?

Without confirmed LIPTRUZET launch and market-by-market sales data, the only defensible “trajectory” is a class-based pattern of how fixed-dose statin-ezetimibe products typically behave post-launch:

Expected lifecycle shape

1. Launch ramp: growth from formulary inclusion and prescriber familiarity.
2. Consolidation: steady demand where coverage favors FDC use and adherence benefits are rewarded.
3. Erosion: net sales decline when separate generics dominate and payers loosen access to low-cost equivalents.
4. Stabilization (if any): persistence can remain if the FDC has a net-cost edge via rebates or if separate therapy remains administratively burdensome.

Key performance metrics to track (business actionable)

• Net price trend (gross-to-net), not list price.
• Market share by segment (primary hyperlipidemia vs mixed dyslipidemia).
• Rebate rate changes in payer contracting cycles.
• Persistence and refill rates vs separate-pill therapy.
• Formulary status changes across Top-10 payers (tier movement is the biggest leading indicator of volume erosion).

---

Bottom-up risks that can accelerate erosion

• Therapeutic interchange: pharmacies and PBMs can substitute to cheaper equivalents without clinical review if PA policies are weak.
• Contracting cycles: a single formulary renegotiation can cause step-down volume.
• Competitive FDCs: if alternative combinations enter with better net cost, LIPTRUZET share can shift quickly.
• Clinical guideline shifts: if guidelines change the threshold for adding ezetimibe, combination initiation rates can move.

---

Key Takeaways

• LIPTRUZET is positioned in a high-volume dyslipidemia segment where formulary access, rebates, and patient persistence drive performance more than product novelty.
• The expected market pattern for an ezetimibe plus atorvastatin FDC is launch ramp, then net price pressure and volume erosion as component generics and competing alternatives gain payer favor.
• A precise financial trajectory for LIPTRUZET cannot be stated from the provided information because market- and date-specific inputs (launch dates, patent/exclusivity expiration, generic entry timing, and observed sales) are not included.
• The most business-critical leading indicators are net price, formulary tier movement, and rebate intensity, followed by persistence versus separate generic therapy.

---

FAQs

1. What market segment does LIPTRUZET target?
   Patients requiring both atorvastatin and ezetimibe for lipid lowering, including mixed dyslipidemia and primary hyperlipidemia where combination therapy helps reach LDL-C goals.

2. What most determines LIPTRUZET net revenue in the US and other large markets?
   Gross-to-net outcomes driven by payer rebates and formulary tier placement, plus the level of preferred coverage versus separate generic atorvastatin and ezetimibe.

3. Why do fixed-dose combinations face faster pricing pressure than separate generics?
   Because payers can often match therapeutic outcomes using lower-cost component generics, making FDC premiums hard to sustain once coverage incentivizes cost-minimization.

4. What is the biggest leading indicator of volume erosion for an FDC like LIPTRUZET?
   Formulary status changes (tier drops, step edits, or PA tightening) that shift prescribing and pharmacy dispensing behavior.

5. How should investors monitor LIPTRUZET performance over time?
   Track net price trend, market share by segment, rebate rate changes, persistence/refill rates, and payer policy shifts across major formularies.

---

References

[1] No sources were provided in the input text.